Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1371/journal.pone.0142212 http://scihub22266oqcxt.onion/10.1371/journal.pone.0142212 C4659681!4659681 !26605551     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26605551 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       PLoS+One 2015 ; 10 (11 ): e0142212 Nephropedia Template TP {{tp|p=26605551 |t=2015. Long-Acting Beta Agonists Enhance Allergic Airway Disease |pdf=|usr=}}{{26605551 }} gab.com Text Long-Acting Beta Agonists Enhance Allergic Airway Disease JO: PLoS One http://www.kidney.de/pget.php?&tw=1&pmid=26605551 #FOAvip Asthma is one of the most common of medical illnesses and is treated in part by drugs that activate the beta-2-adrenoceptor (?2-AR) to dilate obstructed airways. Such drugs include long acting beta agonists (LABAs) that are paradoxically linked to excess asthma-related mortality. Here we show that LABAs such as salmeterol and structurally related ?2-AR drugs such as formoterol and carvedilol, but not short-acting agonists (SABAs) such as albuterol, promote exaggerated asthma-like allergic airway disease and enhanced airway constriction in mice. We demonstrate that salmeterol aberrantly promotes activation of the allergic disease-related transcription factor signal transducer and activator of transcription 6 (STAT6) in multiple mouse and human cells. A novel inhibitor of STAT6, PM-242H, inhibited initiation of allergic disease induced by airway fungal challenge, reversed established allergic airway disease in mice, and blocked salmeterol-dependent enhanced allergic airway disease. Thus, structurally related ?2-AR ligands aberrantly activate STAT6 and promote allergic airway disease. This untoward pharmacological property likely explains adverse outcomes observed with LABAs, which may be overcome by agents that antagonize STAT6. Twit Text FOAVip Long-Acting Beta Agonists Enhance Allergic Airway Disease ????PLoS One http://www.kidney.de/pget.php?&tw=1&pmid=26605551 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26605551 #FOAvip English Wikipedia <ref>{{Cite pmid|26605551 }}</ref> Long-Acting Beta Agonists Enhance Allergic Airway Disease #MMPMID26605551 Knight JM ; Mak G ; Shaw J ; Porter P ; McDermott C ; Roberts L ; You R ; Yuan X ; Millien VO ; Qian Y ; Song LZ ; Frazier V ; Kim C ; Kim JJ ; Bond RA ; Milner JD ; Zhang Y ; Mandal PK ; Luong A ; Kheradmand F ; McMurray JS ; Corry DB PLoS One 2015[]; 10 (11 ): e0142212 PMID26605551 show ga Asthma is one of the most common of medical illnesses and is treated in part by drugs that activate the beta-2-adrenoceptor (?2-AR) to dilate obstructed airways. Such drugs include long acting beta agonists (LABAs) that are paradoxically linked to excess asthma-related mortality. Here we show that LABAs such as salmeterol and structurally related ?2-AR drugs such as formoterol and carvedilol, but not short-acting agonists (SABAs) such as albuterol, promote exaggerated asthma-like allergic airway disease and enhanced airway constriction in mice. We demonstrate that salmeterol aberrantly promotes activation of the allergic disease-related transcription factor signal transducer and activator of transcription 6 (STAT6) in multiple mouse and human cells. A novel inhibitor of STAT6, PM-242H, inhibited initiation of allergic disease induced by airway fungal challenge, reversed established allergic airway disease in mice, and blocked salmeterol-dependent enhanced allergic airway disease. Thus, structurally related ?2-AR ligands aberrantly activate STAT6 and promote allergic airway disease. This untoward pharmacological property likely explains adverse outcomes observed with LABAs, which may be overcome by agents that antagonize STAT6. |Adrenergic beta-2 Receptor Agonists/*adverse effects [MESH] |Albuterol/therapeutic use [MESH] |Animals [MESH] |Anti-Asthmatic Agents/*adverse effects [MESH] |Arrestins/deficiency/genetics [MESH] |Aspergillosis, Allergic Bronchopulmonary/*drug therapy/genetics/metabolism/pathology [MESH] |Aspergillus niger/physiology [MESH] |Asthma/*chemically induced/drug therapy/genetics/metabolism [MESH] |Bronchoconstriction/drug effects [MESH] |Carbazoles/adverse effects [MESH] |Carvedilol [MESH] |Disease Models, Animal [MESH] |Female [MESH] |Formoterol Fumarate/adverse effects [MESH] |Gene Expression [MESH] |Humans [MESH] |Lung/drug effects/metabolism/pathology [MESH] |Mice [MESH] |Mice, Knockout [MESH] |Peptidomimetics/*pharmacology [MESH] |Propanolamines/adverse effects [MESH] |Receptors, Adrenergic, beta-2/deficiency/genetics [MESH] |STAT6 Transcription Factor/agonists/*antagonists & inhibitors/genetics/metabolism [MESH] |Salmeterol Xinafoate/adverse effects [MESH]Long-Acting Beta Agonists Enhance Allergic Airway Disease (epmc).pdf DeepDyve Pubget Overpricing